Advanced Oncotherapy (AVO) – Interim results announcement

Advanced Oncotherapy (AIM: AVO), the developer of a next generation proton therapy system for cancer treatment, announces its unaudited results for the six months ended 30 June 2017 and post-period events.  Highlights: ·     Technological milestones reached with successful integration and testing of proton source, RFQ and SCDTL significantly de-risking development process ·     Progress at the Harley Street […]

Three ways to make proton therapy affordable – Nature Weekly Journal

Three ways to make proton therapy affordable – Nature Weekly Journal by Thomas R Bortfeld & Jay S Loeffler   If cost was not an issue, proton therapy would be the treatment of choice for most patients with localized tumours. Protons can be targeted more precisely than X-rays1, so the tissues around the tumour receive […]

Advanced Oncotherapy (AVO) Chief Ops Officer Ed Lee Q&A with Directors Talk

Advanced Oncotherapy plc (LON:AVO) Chief Operating Officer Ed Lee talks to DirectorsTalk about his background, what that experience brings to AVO and how that knowledge can translate into shareholder value. Transcript below or read on the Directors Talk website here Q1: Ed, thank you for taking time to speak with us. I understand you joined […]

Proton Beam Therapy and CERN Hadron Technology Are Fighting Cancer With LIGHT

Article by Drew Turney at Autodesk Redshift   According to the US National Cancer Institute, nearly 40 percent of Americans will be diagnosed with cancer during their lives. The World Health Organisation names cancer as the second leading cause of death globally, causing nearly one in six deaths. In case anyone needs reminding, cancer is […]

Advanced Oncotherapy (AVO) LIGHT machine trials confirm system on track to treat tumours by end Q3 2018

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, with successful integration of three key elements of the device. The first Side Coupled Drift Tube Linac (“SCDTL”) accelerating module has been integrated with the Radiofrequency Quadrupole […]

Advanced Oncotherapy (AVO) – Director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company, purchased 100,000 ordinary shares of 25 pence in the Company at a price of 17.75 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,223,946 Ordinary Shares, representing 1.51% of the […]